GeneDx Holdings Corp.

For the period ended Dec 31, 2025. Filed Feb 23, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 23, 2026

WGS$54.83-16.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Stockholders' Equity

(in thousands, except share amounts)

Class A Common Stock · Additional paid-in capital · Accumulated deficit · Accumulated other comprehensive income · Total stockholders’ equity
Shares · Par Value
Balance at December 31, 2022	11,773,065	$1	$1,378,125	$(1,124,421)	$—	$253,705
Net loss	—	—	—	(175,767)	—	(175,767)
Common stock issued pursuant to stock option exercises	50,444	—	285	—	—	285
Stock-based compensation expense	—	—	(326)	—	—	(326)
Vested restricted stock units converted to common stock	431,671	—	—	—	—	—
Issuance of common stock in registered direct offering, net of issuance costs	676,868	—	7,564	—	—	7,564
Issuance of common stock for first Milestone Payment	701,460	—	6,692	—	—	6,692
Issuance of common stock in underwritten public offering, net of issuance costs	12,315,752	1	135,438	—	—	135,439
Fractional shares issued upon reverse stock split	29,603	—	—	—	—	—
Other comprehensive income, net of tax	—	—	—	—	425	425
Balance at December 31, 2023	25,978,863	$2	$1,527,778	$(1,300,188)	$425	$228,017
Net loss	—	—	—	(52,286)	—	(52,286)
Common stock issued pursuant to stock option exercises	68,453	—	394	—	—	394
Common stock issued pursuant to Perceptive warrant exercise	645,414	—	12,586	—	—	12,586
Stock-based compensation expense	—	—	9,138	—	—	9,138
Vested restricted stock units converted to common stock	471,663	—	—	—	—	—
Common stock issued pursuant to employee stock purchase plan	26,773	—	497	—	—	497
Issuance of common stock in ATM offering, net of issuance costs	825,379	—	46,496	—	—	46,496
Other comprehensive income, net of tax	—	—	—	—	405	405
Balance at December 31, 2024	28,016,545	$2	$1,596,889	$(1,352,474)	$830	$245,247
Net loss	—	—	—	(21,021)	—	(21,021)
Common stock issued pursuant to stock option exercises	140,847	—	2,022	—	—	2,022
Stock-based compensation expense	—	—	32,162	—	—	32,162
Vested restricted stock units converted to common stock	638,339	1	—	—	—	1
Common stock issued pursuant to employee stock purchase plan	50,615	—	2,961	—	—	2,961
Issuance of common stock in ATM offering, net of issuance costs	398,950	—	46,704	—	—	46,704
Other comprehensive income, net of tax	—	—	—	—	106	106
Balance at December 31, 2025	29,245,296	$3	$1,680,738	$(1,373,495)	$936	$308,182

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.